Type 2 diabetes

Overeating and starving both damage the liver: Cavefish provide new insight into fatty liver disease

Retrieved on: 
Thursday, March 14, 2024
Fatty liver disease, Cirrhosis, Liver failure, Life Science Alliance, Type, DSM-IV codes, Liver, Obesity, Exercise, Gene expression, FNRS, Disease, Assistant, Iowa State University, Associate, National Science Foundation, Zebrafish, Research, Food, NIH, Human, Biology, Atrophy, Type 2 diabetes, Mexican, NSF, Starvation, Fruit, Medical research, Liver disease, Bangladesh Technical Education Board, Animal, Dietary supplement

KANSAS CITY, Mo., March 14, 2024 /PRNewswire/ -- Fatty liver, which can lead to liver damage and disease, can occur from both overeating and starvation. Now, new research shows how naturally starvation-resistant cavefish, unlike other animals, are able to protect their liver and remain healthy. The findings have implications for understanding and potentially addressing liver conditions in humans.

Key Points: 
  • KANSAS CITY, Mo., March 14, 2024 /PRNewswire/ -- Fatty liver, which can lead to liver damage and disease, can occur from both overeating and starvation.
  • Now, new research shows how naturally starvation-resistant cavefish, unlike other animals, are able to protect their liver and remain healthy.
  • "We have discovered for the first time an organism – cavefish—that can avoid fatty liver under starvation conditions," said Cobham.
  • "Fatty liver can result in complications like liver cirrhosis and liver failure.

New Research from Dario Demonstrates Ability to Deliver Improved Health Outcomes with Integrated Solution for Members Managing Weight and Blood Glucose with or without GLP-1 Medications

Retrieved on: 
Tuesday, March 12, 2024
Control, Single-frequency network, Conference, ATTD, Disease, Risk, Weight loss, Blood, Diabetes, Doctor of Philosophy, MD, Type 2 diabetes, Vaccination, A1C, BMI, Prediabetes, Medical device

NEW YORK, March 12, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced today two new clinical studies presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) 2024, held March 6 – 9 in Florence, Italy.

Key Points: 
  • Dario's cardiometabolic solution integrates digital tools, connected devices and intelligent technologies to deliver a personalized and integrated experience to help drive better outcomes through effective behavior change.
  • Today, members can utilize the Dario solution with or without a GLP-1 medication and receive support tailored to their unique need.
  • The first study presented at ATTD analyzed the data of members engaged in Dario's cardiometabolic solution to manage pre-diabetes, a condition that requires weight loss and regulation of A1c.
  • A second Dario study presented at ATTD evaluated the effectiveness of Dario's digital health solution as a means to improve flu vaccine awareness and rates.

Gut bacteria and the immune system: How aging changes the microbiome and can lead to ‘inflammaging’

Retrieved on: 
Wednesday, April 3, 2024
Research, Inflammation, Inflammaging, Health, Red meat, Vitamin, Bacillota, Nutrient, Archaea, Cell, Environment, Disease, Infection, Homeostasis, Probiotic, Risk, Dysbiosis, Gastrointestinal tract, Extrapyramidal system, Tissue, Actinomycetota, Fungus, Bacteria, Virus, University, Life, Pseudomonadota, Type 2 diabetes, Diet, Nutritional science, Mucus, Immune system, Cellular senescence, Family, Stomach, Antigen, Type 2, Vaccine

Research has shown that changes to the composition and diversity of the microorganisms in the gut may explain these differences in immune system aging.

Key Points: 
  • Research has shown that changes to the composition and diversity of the microorganisms in the gut may explain these differences in immune system aging.
  • However, as the composition of our gut microbiome changes with age, a low level of inflammation can become constant throughout the body.
  • Let’s take a closer look at the gut microbiome and how it changes with age.

Gut microbiome imbalances in older adults

  • In fact, compared to other parts of the body, the gut microbiome has the largest number of bacteria.
  • In a healthy gut microbiome, there are four dominant families (or phyla) of microorganisms, including Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria.
  • Firmicutes and Bacteroidetes make up around 80 to 90 per cent of the gut microbiota in the digestive tract.
  • Over time, the shortage of beneficial bacteria such as Firmicutes in older adults starts to compromise the integrity of their intestinal barrier, causing it to become leaky.

How inflammaging works

  • Inflammaging creates an environment that is prone to inflammation, which is caused and maintained by several factors.
  • These can include microorganism imbalances in the intestines (microbial dysbiosis), psychological stress, physical inactivity, poor nutrition and chronic infections.

Maintaining a healthy balance of gut microbiota

  • More specifically, probiotics help improve the function of the intestinal barrier and regulate immune responses by modifying the composition of the gut microbiome.
  • It is clear that the immune system has an intricate relationship with the gut microbiome.
  • A healthy and well-balanced gut microbiome will strengthen the intestinal barrier, which helps to reduce inflammation throughout the body and support the immune system.
  • To achieve this, it is important to maintain a healthy and well-balanced lifestyle as we grow older.


Narveen Jandu does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology

Retrieved on: 
Thursday, March 7, 2024
SAN, EFX, T2D, Diarrhea, Liver injury, Obesity, ALT, Nausea, ELF, DSM-IV codes, Type 2 diabetes, Safety, MASH, Diabetes, Histology, Therapy, Lipid metabolism, Patient, Fibrosis, NASH, Appetite, Hepatology, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease, today announced publication of results in Clinical Gastroenterology and Hepatology from an expansion cohort (Cohort D, N=31) of the Phase 2b SYMMETRY study.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease, today announced publication of results in Clinical Gastroenterology and Hepatology from an expansion cohort (Cohort D, N=31) of the Phase 2b SYMMETRY study.
  • Tolerability of EFX on top of GLP-1RA (N=21 patients) was generally comparable to GLP-1RA alone (placebo, N=10).
  • The most frequent adverse events for EFX-treated patients were grade 1 or 2 gastrointestinal events (diarrhea, nausea, and increased appetite).
  • Patients treated with EFX plus GLP-1RA showed a similar mean weight loss from baseline relative to patients treated with GLP-1RA alone.

Teladoc Health Expands Obesity & Weight Management Capabilities

Retrieved on: 
Thursday, March 7, 2024
Pharmacy, Diabetes, Mental health, Recurrence, Obesity, Health, C-peptide, Weight loss, Sleep, Stroke, TDOC, Type 2 diabetes, Hypertension, Teladoc Health, Health insurance

The multidisciplinary care model is designed by clinicians experienced in obesity medicine and delivered with a tailored approach to weight management.

Key Points: 
  • The multidisciplinary care model is designed by clinicians experienced in obesity medicine and delivered with a tailored approach to weight management.
  • Clients can provide their populations with comprehensive and integrated clinical care, that also addresses wellbeing, mental health and social drivers of health in a personalized manner,” said Dr. Vidya Raman-Tangella, Teladoc Health Chief Medical Officer.
  • The Comprehensive Weight Management solution is customized for health plans and employers to meet the needs of their populations and reduce the cost of care for obesity-related medical expenses by going beyond care coordination to deliver:
    An evidence-based, personally tailored approach inclusive of comprehensive support from providers experienced in obesity management, health coaching, medical nutrition therapy, and integrated, highly accessible mental health support.
  • More information on Teladoc Health’s obesity and weight management programs can be found here .

Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function

Retrieved on: 
Wednesday, March 6, 2024
Type 2 diabetes, Week, PD, Treatment, Cancer, Food, GLP1, Conference, ATTD, Biomarker, Hypoglycemia, DSM-IV codes, Area studies, Poster, C-peptide, Osteopathic medicine in Canada, Pharmaceutical industry

REDWOOD CITY, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, today announced three poster presentations presenting long-term 26 week follow-up data from patients treated with BMF-219, enrolled in the escalation portion of the ongoing Phase II clinical study (COVALENT-111), at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) taking place in Florence, Italy from March 6-9, 2024. This clinical data from all dosing cohorts initiated to date as of February 12, 2024 from the Escalation Phase of COVALENT-111 will be featured during a Poster Discussion Presentation and two Poster Viewing Presentations at ATTD. Biomea will showcase the following three e-poster presentations:

Key Points: 
  • Please find a link here to our website where the poster presentations and discussion will be available.
  • A higher proportion of patients treated with 200mg QD achieved a clinically significant reduction in HbA1c compared to 100mg QD dosing.
  • A durable glycemic response (≥1.0% HbA1C reduction) was seen in 20% and 36% of patients in once daily 100 mg and 200 mg cohorts, respectively.
  • A PK study further assessing the optimal use of BMF-219 to ensure minimal variability of exposure is currently under way.

embecta-sponsored Educational Symposium and Abstracts at ATTD Highlight Role of Insulin Pumps in the Management of Type 2 Diabetes

Retrieved on: 
Wednesday, March 6, 2024
Knowledge, Division, Endocrinology, T2D, Inborn errors of metabolism, Metabolism, Education, Treatment, Insulin, Physician, Quality of life, ATTD, Faculty, DNP, University, Type 2 diabetes, EMBC, MDI, Fortezza, Case Western Reserve University, Patient, D.O, Poster, Needlestick injury, Risk, Lipohypertrophy, Obesity, Research, Fortezza da Basso, Time in Europe

Additionally, six embecta-sponsored abstracts focusing on injection and insulin pump therapies have been selected for presentation as scientific posters at ATTD 2024.

Key Points: 
  • Additionally, six embecta-sponsored abstracts focusing on injection and insulin pump therapies have been selected for presentation as scientific posters at ATTD 2024.
  • Entitled “Unlocking the potential of insulin pumps for personalized T2D care,” the symposium aims to highlight the significance of insulin pump therapy among the extensive treatment options available for type 2 diabetes (T2D).
  • The six embecta-sponsored abstracts set for presentation as scientific posters, include robust data about insulin therapy via both pumps and multiple daily injections (MDI).
  • Another poster highlights data showing that in individuals with type 2 diabetes, insulin pump therapy eases constraints imposed by diabetes management and improves quality of life.

REMSleep Holdings Shareholder Update

Retrieved on: 
Monday, March 4, 2024
ISO, Blood pressure, Incidence, Ageing, Heart, Woman, Inhalation, Atmosphere, International Organization (journal), Dementia, CPAP, OSA, Obstructive sleep apnea, Pressure, Obesity, FDA, OTC, Smoking, Arrhythmia, Sleep, Biocompatibility, Exhalation, CHF, Risk, International Organization for Standardization, Consultant, Type 2 diabetes, Frustration, Engineering, BMI, DSM-IV codes, Non-invasive ventilation, Type, National Council, Respiration, Medical device

CLEARWATER, FL, March 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - REMSleep Holdings, Inc. (OTC PINK: RMSL) gives an update on FDA process and REMSleep status.

Key Points: 
  • CLEARWATER, FL, March 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - REMSleep Holdings, Inc. (OTC PINK: RMSL) gives an update on FDA process and REMSleep status.
  • We have had numerous inquiries asking for REMSleep regulatory status update.
  • REMSleep consultants are confident we will receive our 510(K) and we will never give up until we are successful.
  • REMSleep has addressed this problem by developing a novel CPAP nasal pillow interface that has been engineered to reduce pressure and enable better airflow.

3 Tips to Nourish Your Body for National Nutrition Month in March

Retrieved on: 
Monday, March 4, 2024
Nut, Diet, Chopped, Mineral, Vitamin, Skin, Food, Grain boundary strengthening, Risk, Seed, Health, Vegetable, Type 2 diabetes, Yogurt, Digestion, Lettuce, Taste, Colorectal cancer, Dietary supplement

Oakville, Ontario, March 04, 2024 (GLOBE NEWSWIRE) -- In Canada, March marks National Nutrition Month, a time to reevaluate our understanding of food and its impact on our health.

Key Points: 
  • Oakville, Ontario, March 04, 2024 (GLOBE NEWSWIRE) -- In Canada, March marks National Nutrition Month, a time to reevaluate our understanding of food and its impact on our health.
  • We know that the amount of information (and disinformation) about nutrition can be overwhelming.
  • Here are 3 tips to nourish your body, enhance your daily eating and support your overall well-being:
    Not all calories are created equal.
  • So, in celebration of National Nutrition Month in March, why not give these 3 strategies a try.

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

Retrieved on: 
Monday, March 4, 2024
Incidence, CGM, Doctor of Philosophy, Level 2, MD, FDA, Quality of life, IROS, Safety, Diabetes, Therapy, Type 2 diabetes, Patient, Insulin, T1D, Pharmaceutical industry

This randomized, double-blind, placebo-controlled trial is expected to enroll approximately 150 patients at up to 20 sites in the United States, with the first patient expected to be enrolled in the second quarter of 2024.

Key Points: 
  • This randomized, double-blind, placebo-controlled trial is expected to enroll approximately 150 patients at up to 20 sites in the United States, with the first patient expected to be enrolled in the second quarter of 2024.
  • The Phase 3 study will assess two doses of orally administered cadisegliatin versus placebo in patients currently being treated with multiple daily insulin injections and continuous subcutaneous insulin infusion, who use a continuous glucose monitor (CGM).
  • The primary efficacy endpoint of the study will compare the incidence of Level 2 or Level 3 hypoglycemic events between cadisegliatin-treated subjects and those in the placebo group.
  • Cadisegliatin is not yet licensed or approved anywhere globally and has not been demonstrated to be safe or effective for any use.